Invox Pharma Limited

Matthew Lakins

Mihriban Tuna

Jose Munoz-Olaya

Francisca Wollerton

Sachin Badrinath Surade

Michael Dyson

Sarah Batey

Alexander Koers

Sarka Pechouckova

Mateusz Wydro

The present application relates to antibody molecules that bind both PD-L1 and CD 137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.

Antibody molecules that bind PD-L1 and CD137

The present disclosure, in some aspects, provides antibody molecules, or antigen-binding fragments thereof capable of binding specifically to PD-L1. The present disclosure further provides antibody molecules, or antigen-binding fragments thereof capable of binding specifically to PD-L1 and a second antigen-binding site. Methods of making and/or using such antibody molecules or antigen bending fragments are also provided.

Antibody molecules

The invention relates to specific binding members that bind CD137. The specific binding members comprise a CD137 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.

Fc binding fragments comprising a CD137 antigen-binding site

Growing community of inventors

Cambridge, United Kingdom

Matthew Lakins